A Multi-center, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.

This article provides information about a newly launched clinical trial in China for a drug called YK012, which is being tested in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of YK012, and it is the first-in-human trial for this drug. The study will involve administering YK012 to patients through intravenous infusion every two weeks for a treatment cycle of four weeks. The primary outcome measures include assessing adverse events, dose-limiting toxicity, and determining the maximum tolerated dose for further clinical trials. The trial is currently recruiting participants, with a target enrollment of 48 individuals, and the primary investigator is Yuankai Shi from the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. [Extracted from the article]